Okee Williams retweeted
🩺🤖 New study shows OpenAI's o1 model meets or surpasses human physicians in tackling the toughest diagnostic cases in medicine 🧠📚. It's clear that very soon, *not* using AI could be seen as offering suboptimal care. Full paper here: arxiv.org/pdf/2412.10849
Okee Williams retweeted
Link to report:
redeye.se/research/1063718/r…
Okee Williams retweeted
XBI's strength many times depends on M&A's momentum - as shown by RBC's analysis below
Dont miss @microcap_redeye Microcap report. Full of interesting data analysis. Free access for now! @Redeye #microcap
The first Redeye Quality Microcap report was just released.
At 80+ pages, it features commentary on 17 names, an analysis of the Swedish market sentiment, and an interview with none other than @IanCassel.
Available for free using the link below:
redeye.se/research/1038885/r…
2
196
Don’t miss Redeye’s latest sector report, Quality Microcap, now available! Also check out our newly released report on SaaS and IT Consulting.
Redeye provides its first ever sector update for the Swedish microcap space. We introduce the Quality Microcap theme, discuss the 14 target companies in our covered universe and evaluate whether microcaps are set to outperform.
redeye.se/research/1038885/r…
141
Okee Williams retweeted
Redeye initiates coverage of Cheffelo, the second-largest provider of meal kits in the Nordic market. As one of the few actors with solid cash generation in an industry seeing investment outflows, Cheffelo holds a strong position.
$CHEF
redeye.se/research/1037807/c…
Okee Williams retweeted
Redeye updates on Calliditas, stating that the company delivered a positive surprise in total sales, including royalty contributions from Asia, US patient enrollment and new subscribers.
$CALTX
redeye.se/research/1030013/c…
Okee Williams retweeted
OS-SEMIFINAL! 🤩🇸🇪 18-åriga Tara Babulfath besegrar världsettan Assunta Scutto i judo.
📲 Streama varje ögonblick från OS i Paris 2024 – bara på Max

This media is unavailable
Okee Williams retweeted
Redeye's Growth Day 2024 is LIVE!
Schedule:
09.00-09.20: Cinclus Pharma & Moberg Pharma
09.20-09.40: Active Biotech & Flerie
09.40-10.00: Medivir & Episurf Medical
10.00 - 10.20: Cantargia & Devyser
Tune in:
redeye.se/events/981085/rede…
Okee Williams retweeted
This is what we do.
To show you the real cyborg Vasyl Zelenevich, who lost two hands while defending Ukraine, thanks to the technology of @IntegrumOsseo , we are returning the bionic hands that he will control thanks to the technology @CoaptControl
Реквізити:
send.monobank.ua/jar/8FAySL8…
PayPal:
[email protected]
Okee Williams retweeted
Next up one the Redeye Theme: Commercialization in Life Science event are:
10.50-11:10: Newbury Pharma
11:10-11:30: Xspray Pharma
11:30-11:50: Oncopeptides
11:50-12:10: Xbrane
12:10-12:30: Senzime
Tune in:
redeye.se/events/972681/rede…
Okee Williams retweeted
Vår företrädesemission fulltecknades och bolaget tillförs cirka 17,7 MSEK före avdrag för emissionskostnader.
Läs hela PM:et här 👇🏻 coeginpharma.com/investor-re…
Okee Williams retweeted
Biopharma YTD Performance:
India Pharma >> $XBI > Shanghai SSE > European Pharma > Japan > China Pharma
Okee Williams retweeted
Redeye increases its base case for Alligator Bioscience after the positive topline results from OPTIMIZE-1, the phase II study of mitazalimab in pancreatic cancer.
$ATORX
redeye.se/research/972986/al…
Congratulations to Alligator Bioscience that announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer mfn.se/a/alligator-bioscienc…
214
Okee Williams retweeted
Redeye's analyst comments on Calliditas preliminary Q4 update from earlier today.
$CALTX
redeye.se/research/969535/ca…

























